Cargando…
CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
Chimeric antigen receptor (CAR) T‐cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the current times. As the clinical use has progressed rather rapidly since the first approval...
Autores principales: | Taneja, Alankrita, Jain, Tania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175816/ https://www.ncbi.nlm.nih.gov/pubmed/35844301 http://dx.doi.org/10.1002/jha2.350 |
Ejemplares similares
-
How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023) -
Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
por: Xia, Yuan, et al.
Publicado: (2022) -
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022) -
Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021) -
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)